Description

Corcept Therapeutics’ Lifyorli Launch Reaches 1,300 Patients — Can Adoption Accelerate?

Corcept Therapeutics reported second quarter 2026 revenues of $256.1 million, marking a 32% year-over-year increase. The company’s endocrinology segment contributed $208.6 million through Korlym and authorized generic products, while Lifyorli, its oncology drug launched in early 2026, generated $47.6 million in its first quarter. Net income rose to $43 million from $35 million in the prior-year period, with operating expenses remaining flat sequentially. Cash and investments totaled $545 million at June 30. Corcept raised its 2026 revenue guidance to a range of $1.1 billion to $1.2 billion, reflecting strength across both endocrinology and oncology businesses. Growth in the endocrinology division centers on increasing awareness and diagnosis of hypercortisolism, a condition linked to resistant diabetes and hypertension that is often underdiagnosed due to overlapping symptoms with more common diseases.